Virtu Financial LLC Sells 47,031 Shares of Tonix Pharmaceuticals Holding Corp. $TNXP

Key Points

• Virtu Financial LLC has significantly reduced its holdings in Tonix Pharmaceuticals by 73.6%, now owning approximately 16,878 shares worth about $302,000.
• Tonix Pharmaceuticals reported a net loss of ($3.86) per share for its latest quarter, missing expectations and reflecting a negative return on equity of 57.93%.
• Analysts have recently upgraded the company's stock rating from “sell” to “hold”, while another firm reiterated a “buy” rating, indicating mixed sentiments on future performance.

Virtu Financial LLC decreased its position in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) by 73.6% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 16,878 shares of the company's stock after selling 47,031 shares during the period. Virtu Financial LLC owned 0.26% of Tonix Pharmaceuticals worth $302,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the company. Geode Capital Management LLC boosted its position in Tonix Pharmaceuticals by 1,600.1% during the fourth quarter. Geode Capital Management LLC now owns 1,971,894 shares of the company's stock valued at $650,000 after purchasing an additional 1,855,907 shares during the last quarter. Jane Street Group LLC raised its holdings in Tonix Pharmaceuticals by 5,932.3% during the fourth quarter. Jane Street Group LLC now owns 1,662,682 shares of the company's stock valued at $548,000 after buying an additional 1,635,119 shares in the last quarter. Point72 Asset Management L.P. bought a new position in Tonix Pharmaceuticals during the fourth quarter valued at about $526,000. Northern Trust Corp bought a new position in Tonix Pharmaceuticals during the fourth quarter valued at about $162,000. Finally, Two Sigma Investments LP bought a new position in Tonix Pharmaceuticals during the fourth quarter valued at about $66,000. Institutional investors and hedge funds own 82.26% of the company's stock.

Tonix Pharmaceuticals Trading Down 0.6%

TNXP traded down $0.20 on Thursday, hitting $35.85. 1,100,746 shares of the stock traded hands, compared to its average volume of 2,214,269. Tonix Pharmaceuticals Holding Corp. has a 52 week low of $6.76 and a 52 week high of $130.00. The firm has a market capitalization of $314.40 million, a PE ratio of -0.91 and a beta of 1.70. The business has a fifty day moving average price of $41.36 and a two-hundred day moving average price of $27.40.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last issued its quarterly earnings results on Monday, August 11th. The company reported ($3.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.10) by ($0.76). Tonix Pharmaceuticals had a negative net margin of 828.22% and a negative return on equity of 57.93%. The firm had revenue of $2.00 million for the quarter, compared to the consensus estimate of $2.60 million. On average, equities research analysts forecast that Tonix Pharmaceuticals Holding Corp. will post -1762.5 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. Wall Street Zen upgraded Tonix Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday, June 7th. Alliance Global Partners restated a "buy" rating on shares of Tonix Pharmaceuticals in a report on Tuesday, June 3rd. Two research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Tonix Pharmaceuticals has an average rating of "Buy" and an average target price of $70.00.

Tonix Pharmaceuticals Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.